Cipla gets EIR from USFDA for Invagen manufacturing facility

"Following the inspection by the United States Food and Drug Administration (USFDA) at the lnvagen (US) manufacturing facility from December 2, 2019 to December 6, 2019, the company has received the establishment inspection report (EIR), indicating closure of the inspection," Cipla said in a filing to BSE.

from Moneycontrol Business News https://ift.tt/2U0eKCI